drugset / Trial / NCT01202227

An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain

NCT01202227

Phase 3 Completed 104 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety of the long-term use of pregabalin at doses up to 600 mg/day in patients with central neuropathic pain (post spinal cord injury pain, post stroke pain, and multiple sclerosis pain).

Timeline

Start
2010-09
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 150 mg
Subject Pregabalin Small molecule 600 mg